tetano
Editor, Senior Moderator
Circ J
. 2021 Apr 29.
doi: 10.1253/circj.CJ-21-0087. Online ahead of print.
Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors
Yuji Ikari[SUP] 1 [/SUP], Yuya Matsue[SUP] 2 3 [/SUP], Sho Torii[SUP] 1 [/SUP], Misaki Hasegawa[SUP] 1 [/SUP], Kazuki Aihara[SUP] 1 [/SUP], Shunsuke Kuroda[SUP] 4 5 [/SUP], Takahide Sano[SUP] 6 7 [/SUP], Takeshi Kitai[SUP] 8 [/SUP], Taishi Yonetsu[SUP] 9 [/SUP], Shun Kohsaka[SUP] 10 [/SUP], Takuya Kishi[SUP] 11 [/SUP], Issei Komuro[SUP] 12 [/SUP], Ken-Ichi Hirata[SUP] 13 [/SUP], Koichi Node[SUP] 14 [/SUP], Shingo Matsumoto[SUP] 6 [/SUP]
Affiliations
Abstract
Background: Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).Methods and Results:In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus.
Conclusions: This study suggests the potential benefits of statins use against COVID-19.
Keywords: Cardiovascular risk factors; Coronavirus disease 2019 (COVID-19); Statin.
. 2021 Apr 29.
doi: 10.1253/circj.CJ-21-0087. Online ahead of print.
Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors
Yuji Ikari[SUP] 1 [/SUP], Yuya Matsue[SUP] 2 3 [/SUP], Sho Torii[SUP] 1 [/SUP], Misaki Hasegawa[SUP] 1 [/SUP], Kazuki Aihara[SUP] 1 [/SUP], Shunsuke Kuroda[SUP] 4 5 [/SUP], Takahide Sano[SUP] 6 7 [/SUP], Takeshi Kitai[SUP] 8 [/SUP], Taishi Yonetsu[SUP] 9 [/SUP], Shun Kohsaka[SUP] 10 [/SUP], Takuya Kishi[SUP] 11 [/SUP], Issei Komuro[SUP] 12 [/SUP], Ken-Ichi Hirata[SUP] 13 [/SUP], Koichi Node[SUP] 14 [/SUP], Shingo Matsumoto[SUP] 6 [/SUP]
Affiliations
- PMID: 33952833
- DOI: 10.1253/circj.CJ-21-0087
Abstract
Background: Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).Methods and Results:In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus.
Conclusions: This study suggests the potential benefits of statins use against COVID-19.
Keywords: Cardiovascular risk factors; Coronavirus disease 2019 (COVID-19); Statin.